ANCA Testing in Clinical Practice: From Implementation to Quality Control and Harmonization

J. Damoiseaux*

*Corresponding author for this work

Research output: Contribution to journal(Systematic) Review article peer-review

1 Citation (Web of Science)
20 Downloads (Pure)

Abstract

Analyses for the presence of anti-neutrophil cytoplasmic antibodies (ANCA) are important in the diagnostic work-up of patients with small vessel vasculitis. Since current immuno-assays are predominantly designed for diagnosis of patients with ANCA-associated vasculitis (AAV), implementation in routine clinical practice, internal and external quality control, and harmonization are focused on this particular use. However, ANCA testing may also be relevant for monitoring therapy efficacy and for predicting a clinical relapse in AAV patients, and even for diagnostic purposes in other clinical situations. In the current review, the topics of implementation, quality control, and standardization vs. harmonization are discussed while taking into account the different applications of the ANCA assays in the context of AAV.
Original languageEnglish
Article number656796
Number of pages8
JournalFrontiers in Immunology
Volume12
DOIs
Publication statusPublished - 16 Mar 2021

Keywords

  • harmonization
  • myeloperoxidase
  • proteinase 3
  • standardization
  • vasculitis
  • DIAGNOSIS
  • STANDARDIZATION
  • GATING POLICY
  • FOLLOW-UP
  • VASCULITIS
  • INTERNATIONAL CONSENSUS STATEMENT
  • ANTINEUTROPHIL CYTOPLASMIC ANTIBODIES
  • IMMUNOASSAY

Cite this